5,151 Shares in Encompass Health Corporation $EHC Acquired by Inceptionr LLC

Inceptionr LLC acquired a new position in shares of Encompass Health Corporation (NYSE:EHC) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,151 shares of the company’s stock, valued at approximately $497,000.

Several other large investors have also bought and sold shares of EHC. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Encompass Health by 3,059,159.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after purchasing an additional 3,793,358 shares during the last quarter. Norges Bank acquired a new stake in Encompass Health in the fourth quarter valued at approximately $133,221,000. Price T Rowe Associates Inc. MD grew its stake in shares of Encompass Health by 24.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after buying an additional 948,202 shares during the last quarter. Millennium Management LLC increased its holdings in shares of Encompass Health by 140.0% during the third quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock worth $155,430,000 after buying an additional 713,738 shares in the last quarter. Finally, 8 Knots Management LLC acquired a new stake in shares of Encompass Health during the 2nd quarter valued at $78,644,000. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Stock Up 1.4%

Shares of NYSE EHC opened at $112.66 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.76. The firm has a market cap of $11.18 billion, a PE ratio of 18.81, a P/E/G ratio of 2.46 and a beta of 0.74. The company’s fifty day simple moving average is $104.97 and its 200 day simple moving average is $103.80. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 30th. The company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The firm’s revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.37 EPS. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. As a group, sell-side analysts forecast that Encompass Health Corporation will post 5.96 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Thursday, October 1st will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Thursday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s payout ratio is 12.69%.

Analyst Ratings Changes

Several research firms have recently issued reports on EHC. Leerink Partners set a $152.00 price objective on Encompass Health in a research note on Friday, May 22nd. Weiss Ratings lowered shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, June 26th. Wall Street Zen upgraded Encompass Health from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Barclays cut their target price on Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a report on Tuesday, May 5th. Finally, TD Cowen assumed coverage on Encompass Health in a research report on Thursday, May 28th. They issued a “buy” rating and a $125.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $143.86.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president owned 24,755 shares in the company, valued at approximately $2,588,382.80. This trade represents a 2.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.80% of the stock is owned by insiders.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.